Advances in the application of thiopurines in the treatment of inflammatory bowel disease
10.3760/cma.j.cn101480-20240913-00106
- VernacularTitle:巯嘌呤类药物在炎症性肠病中的应用进展
- Author:
Caiyun LONG
1
;
Ying HUANG
1
Author Information
1. 国家儿童医学中心 复旦大学附属儿科医院消化科，上海 201102
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Thiopurines;
Pharmacogenomics
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(4):339-344
- CountryChina
- Language:Chinese
-
Abstract:
Inflammatory bowel disease (IBD) is one of the common diseases of the digestive system, characterized by recurrent chronic intestinal inflammation. Despite the introduction of new biological agents and small molecule drugs into clinical practice, thiopurines continue to play an important role as first-line therapy for IBD, yet the adverse reactions associated with these drugs should not be overlooked. With the widespread adoption of pharmacogenomics, personalized treatment strategies for thiopurines based on genotype and phenotype have gained attention. This review focuses on the mechanisms of thiopurine drugs, application in IBD, and the monitoring of adverse reactions.
